bioRxivCancer Biology
Cannabinoid Combination Targets NOTCH1-Mutated T-ALL Through the Integrated Stress Response Pathway
Abstract
In T-cell acute lymphoblastic leukemia (T-ALL) more than 50% of cases display autoactivation of Notch1 signaling, leading to oncogenic transformation. We have previously identified a specific chemovar of Cannabis that induces apoptosis by preventing Notch1 maturation in leukemia cells. Here, we isolated three cannabinoids from this chemovar that synergistically mimic the effects of the whole extract. Two were previously known, Cannabidiol (CBD) and Cannabidivarin (CBDV); whereas the third cannabinoid, which we termed 331-18A, was identified and fully characterized in this study. We demonstrated that these cannabinoids act through Cannabinoid receptor type 2 and TRPV1 to activate the integrated stress response pathway by depleting intracellular Ca2+. This is followed by increased mRNA and protein expression of ATF4, CHOP and CHAC1, which is hindered by inhibiting the upstream initiation factor eIF2. The increased abundance of CHAC1 prevents Notch1 maturation, thereby reducing the levels of the active Notch1 intracellular domain, and consequently decreasing cell viability and increasing apoptosis. Treatment with the three isolated molecules resulted in reduced tumor size and weight in-vivo and slowed leukemia progression in mice models. Altogether, this study elucidated the mechanism of action of three distinct cannabinoids in modulating the Notch1 pathway, and constitutes an important step in the establishment of a new therapy for treating NOTCH1-mutated diseases and cancers such as T-ALL.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: mechanistic / dynamical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress
A. Melnick, S. Liang, … M. Y. Chiang·bioRxiv·Jan 22, 2023
- Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia
L. Cao, G. A. Ruiz Buendia, … F. Radtke·Blood AdvancesPeer-reviewed·Oct 24, 2023
- A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia
O. Lancho, A. Singh, … D. Herranz·bioRxiv·May 21, 2022
- Development of a Notch pathway assay and quantification of functional Notch pathway activity in T-cell acute lymphoblastic leukemia
Kirsten Cante-Barrett, Laurent Holtzer, … Jules P.P. Meijerink·CancersPeer-reviewed·Oct 27, 2020
- NFAT are Essential and Redundant Actors for Leukemia Initiating Potential in T-cell Acute Lymphoblastic Leukemia
C. Catherinet, D. Passaro, … C. Tran Quang·bioRxiv·Oct 30, 2020
- β-catenin activity induces an RNA biosynthesis program promoting therapy resistance in T Acute Lymphoblastic Leukemia
V. Garcia-Hernandez, D. Arambilet, … A. Bigas·bioRxiv·Jul 7, 2022